Ferinject 500 mg at 1800 vial ferric carboxymaltose injection addresses iron deficiency when oral iron is ineffective or poorly tolerated. This concentrated formulation supports rapid replenishment of iron stores in clinical settings where timely correction is essential.
Each 500 mg vial provides a precise dose of iron complexed with carboxymaltose, enabling controlled distribution and utilization. The 1800 vial packaging is designed for institutional use, ensuring stability and accurate dosing in professional healthcare environments.
| Product Name | Strength | Packaging | Primary Use |
|---|---|---|---|
| Ferinject | 500 mg per vial | 1800 vial carton | Intravenous iron replacement |
| Indication | Iron deficiency anemia | Hospital & clinic supply | When oral iron fails |
| Administration | IV infusion | Prescription only | Professional monitoring required |
| Key Feature | Carboxymaltose complex | Standardized labeling | Dose flexibility |
Mechanism Of Action For Iron Replenishment
Ferric carboxymaltose delivers iron directly into the bloodstream, bypassing slower oral absorption pathways. The complex is taken up by reticuloendothelial cells, where stored ferritin gradually releases bioavailable iron for erythropoiesis.
This mechanism allows for rapid hemoglobin correction in anemic patients with ongoing iron loss or high demand. Unlike some iron salts, the carboxymaltose matrix reduces free iron in plasma, supporting safer distribution to tissues.
Clinical Indications And Dosing Considerations
Approved Patient Populations
Usage is typically considered in adults and pediatric patients with chronic kidney disease, inflammatory conditions, or malabsorption syndromes leading to iron deficiency. Dosing is tailored to baseline ferritin, transferrin saturation, and clinical response.
Typical Administration Protocol
Health professionals calculate total iron deficit using standardized formulas, then plan infusion schedules. Monitoring of hemoglobin and iron biomarkers guides retreatment intervals to maintain stable iron status without overload.
Safety Profile And Monitoring Parameters
Commonly Observed Reactions
Most adverse events are mild to moderate, including headache, infusion-site reactions, and transient increases in blood pressure. Severe hypersensitivity events are rare but require immediate intervention and appropriate facility readiness.
Laboratory Surveillance
Baseline and follow-up tests should include serum ferritin, transferrin saturation, renal function, and hemoglobin. Trend monitoring helps clinicians balance repletion with avoidance of excess iron accumulation in organs.
Handling And Storage Requirements
Vials must be stored at controlled room temperature, protected from moisture and direct light. Before use, inspect solution clarity and container integrity to ensure the product meets sterility and quality standards.
Reconstitution protocols specify solvent type and mixing technique to achieve homogenous suspension. Once prepared, infusion should begin promptly, following institutional policies for compatibility and stability.
Key Takeaways For Prescribers And Patients
- Ferinject 500 mg in 1800 vial format supports reliable iron repletion via intravenous route
- Carboxymaltose complex enables controlled release, reducing free iron-related risks
- Dosing should align with evidence-based guidelines and monitored through serial labs
- Vial handling, reconstitution, and storage practices directly impact safety and efficacy
- Regular follow-up and patient education enhance adherence and early detection of issues
FAQ
Reader questions
How quickly can hemoglobin levels improve after starting therapy
Many patients observe a rise in hemoglobin within 2–4 weeks, with further gains over several months as iron stores are rebuilt. Individual timelines depend on severity, ongoing blood loss, and adherence to follow-up testing.
Can this injection be used during dialysis sessions
Yes, ferric carboxymaltose is often administered in dialysis units under supervision, with dosing aligned with treatment schedules and vascular access considerations. Protocols vary by facility and patient volume status.
Are there specific lab thresholds that warrant therapy
Clinicians typically consider intervention when ferritin remains low or transferrin saturation is below target ranges, guided by condition-specific guidelines. Clinical judgment also weighs symptoms, cardiovascular risk, and anticipated blood loss.
What precautions are necessary for patients with a history of hypersensitivity
Previous hypersensitivity to any iron complex requires detailed risk assessment, possible premedication, and readiness to manage reactions. Gradual dose escalation and observation after initial infusions help identify tolerability early.